- CSR Summary Not Yet Available
- NCT03078907
- Primary Citation
Trial Information
Generic NameSelexipagProduct NameUPTRAVI®Therapeutic AreaRespiratory Tract (Lung and Bronchial) DiseasesEnrollment108% Female71.3%% White88.9%
Product ClassProstacyclin receptor agonistSponsor Protocol NumberAC-065A404Data PartnerJohnson & JohnsonCondition StudiedPulmonary Arterial HypertensionMean/Median Age (Years)49.4
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available